EDGAR Filing Documents for 0001640334-24-001122

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:

SEC Accession No. 0001640334-24-001122

Filing Date

2024-07-16

Accepted

2024-07-16 13:13:09

Documents

Period of Report

2024-07-17

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 6-K	nymox_6k.htm	6-K	11740
2	PRESS RELEASE	nymox_ex991.htm	EX-99.1	14219
3		nymox_ex991img3.jpg	GRAPHIC	4405
4		nymox_ex991img4.gif	GRAPHIC	5307
	Complete submission text file	0001640334-24-001122.txt		40687

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 241119235
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)